Ketorolac Tromethamine 10 mg Tab, 3gm/100ml inj.

Ketofast 10: Each tablet contains Ketorolac Tromethamine USP 10 mg.
Ketofast 30 injection: Each ampoule contains Ketorolac Tromethamine USP 30 mg.

Ketorolac Tromethamine is indicated for the short term management of moderate to moderately severe acute pain that requires analgesia at the opiod level (usually in a postoperative setting).

10 mg every 4 to 6 hours as required. Doses exceeding 40 mg per day are not recommended.
Opioid analgesics (e.g. morphine, pethidine) may be used concomitantly and may be required for optimal analgesic effect in the early postoperative period when pain is most severe. Ketorolac does not interfere with opioid binding and does not exacerbate opioid-related respiratory depression or sedation.
For patients receiving parenteral Ketofast and who are converted to Ketofast oral tablets, the total combined daily dose should not exceed 90 mg (60 mg for the elderly, renally-impaired patients and patients less than 50 kg) and the oral component should not exceed 40 mg on the day the change of formulation is made. Patients should be converted to oral treatment as soon as possible.
The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.
A longer dosing interval, e.g. 6 – 8 hourly, is advisable in the elderly.
Ketofast is not recommended for use in children under 16 years of age.

Ketofast 30 injection:
For adult patients:
(< 65 years): Initial dose is 60 mg IM (single) or 30 mg IV (single). Maintenance dose is 30 mg IM/ IV 6 hourly. Maximum dose is 120 mg/day.
For elderly patients: (> 65 years): Initial dose is 30 mg IM. Maintenance dose is 60 mg/ day. The duration of treatment should not exceed two days.
Ketofast is not recommended for use in children under 16 years of age.

Related Products